What is Saxenda?

What Saxenda is

Saxenda is a once-daily subcutaneous liraglutide injection for chronic weight management. Liraglutide is a GLP-1 receptor agonist with a shorter duration of action than weekly semaglutide, which is why Saxenda is taken every day rather than once a week. The FDA approved Saxenda in 2014 as an adjunct to diet and physical activity.

This article is educational, not medical advice, and not a sales page for Saxenda. Beema Health does not dispense Saxenda. A prescription is required. Completing telehealth intake does not guarantee any prescription. Weight loss is not guaranteed.

Who Saxenda is labeled for

In adults, Saxenda is indicated for chronic weight management in people with BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or dyslipidemia. In pediatric patients 12 years and older, it is indicated when BMI is in the labeled range corresponding to obesity for age and sex. Always check the current label for exact BMI cutoffs and limitations of use.

Saxenda is not indicated for the treatment of type 2 diabetes. Victoza is the liraglutide brand for that purpose. Combining Saxenda with other liraglutide products or with other GLP-1 receptor agonists is not recommended on the label.

Daily injection and titration

Saxenda is injected once daily, at any time, independent of meals, in the abdomen, thigh, or upper arm, rotating sites. The multi-dose pen is dialed to the prescribed dose. Never share the pen, even if the needle is changed.

The labeled adult titration is 0.6 mg daily for one week, then 1.2 mg, 1.8 mg, 2.4 mg, and 3.0 mg, increasing at weekly intervals as tolerated. The recommended maintenance dosage is 3 mg daily. Escalation exists to reduce gastrointestinal side effects. If a patient cannot tolerate an increase, the prescriber may delay it. If 3 mg cannot be tolerated, the prescribing information has historically directed discontinuation because lower doses were not the approved maintenance regimen for weight management. Follow the current label and the prescriber.

Missed-dose instructions are on the Medication Guide (typically: skip the missed dose if more than 12 hours have passed and resume the next day; do not take an extra dose). Confirm on the latest Instructions for Use.

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 and onward: 3 mg once daily (maintenance), if tolerated

What the SCALE trial showed

The SCALE Obesity and Prediabetes trial randomized adults with obesity, or overweight plus dyslipidemia or hypertension, without type 2 diabetes, to liraglutide 3 mg or placebo plus lifestyle intervention for 56 weeks. Mean weight reduction was greater with liraglutide. Gastrointestinal events, especially nausea, were more common with liraglutide and often occurred during dose escalation.

Later SCALE papers and extensions examined weight-loss maintenance and glycemic outcomes in people with prediabetes. Those studies still do not predict one person's result. Saxenda is used long term when a clinician judges the benefit-risk balance remains favorable, similar in spirit to other chronic weight-management medicines.

Boxed warning and other risks

Saxenda carries a boxed warning for thyroid C-cell tumors in rodents. It is unknown whether liraglutide causes medullary thyroid carcinoma in humans. It is contraindicated in personal or family history of MTC or in MEN 2, and after serious hypersensitivity to liraglutide.

Other labeled warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia (especially with insulin or sulfonylureas in people who also have diabetes), heart-rate increase, renal impairment from dehydration, hypersensitivity, and suicidal behavior and ideation monitoring language that has appeared on older liraglutide weight-management labels (always verify whether a warning remains on the current FDA label, because class language is sometimes updated). Pulmonary aspiration during anesthesia is a class concern for GLP-1 receptor agonists.

Common adverse reactions include nausea, diarrhea, constipation, vomiting, injection-site reactions, headache, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase. Seek urgent care for severe abdominal pain that may radiate to the back, symptoms of gallbladder disease, or a serious allergic reaction.

Daily versus weekly GLP-1 medicines

People comparing Saxenda with weekly Wegovy or Zepbound are comparing different labeled products, trial magnitudes, and injection burden. SCALE mean weight change was smaller than later STEP and SURMOUNT programs on average, but that does not make Saxenda 'useless' or weekly medicines automatically 'right.' Tolerability, other medical conditions, and which product a clinician can lawfully prescribe all matter.

Switching from daily liraglutide to a weekly incretin (or the reverse) is not a milligram-for-milligram swap. See switching GLP-1 medications. Beema Health does not offer Saxenda. If you are exploring telehealth medical weight loss, read Beema's program overview. That link is not a claim that Beema will substitute another product for Saxenda.

Frequently asked questions

Sources

1. [1] Saxenda (liraglutide) U.S. Prescribing Information, Novo Nordisk
2. [2] DailyMed: Saxenda (liraglutide) injection
3. [3] Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015.
4. [4] Saxenda (liraglutide) injection, NDA 206321. Drugs@FDA approval and labeling history.